1. Hormone-receptor positive breast cancer: highlights from the 39 TH San Antonio Breast Cancer Symposium.
- Author
-
Zucchini G and Montemurro F
- Subjects
- Antineoplastic Agents, Hormonal administration & dosage, Antineoplastic Agents, Hormonal adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Aromatase Inhibitors administration & dosage, Aromatase Inhibitors adverse effects, Chemotherapy, Adjuvant, Estrogen Receptor Modulators administration & dosage, Estrogen Receptor Modulators adverse effects, Estrogen Receptor Modulators therapeutic use, Female, Humans, Postmenopause, Randomized Controlled Trials as Topic, Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Aromatase Inhibitors therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Breast Neoplasms surgery
- Abstract
The San Antonio Breast Cancer Symposium is considered one of the most influential international meetings focusing on breast cancer management, covering several areas of study from basic research to clinical practice topics. a number of oral presentations addressing hormone receptor-positive breast cancer brought new data about critical subjects like the optimal duration of adjuvant endocrine therapy, new prognostic markers and their potential role in guiding adjuvant treatment choices, new insights into genomic alterations acquired during the metastatic process, and pharmacologic strategies to overcome resistance to endocrine therapy. This article aims at summarizing some of the presentations that, in our opinion, are expected to have an impact on clinical practice and research programs in this patient population.
- Published
- 2017
- Full Text
- View/download PDF